Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection

Documents similaires

• Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.
  par: Stratford, MR, et autres
  Publié: (2011)
• Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection.
  par: Stratford, MR, et autres
  Publié: (2012)
• Enhanced fluorescence detection of cis-combretastatins by post-column photolysis.
  par: Stratford, MR
  Publié: (2008)
• A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation
  par: Stratford, M, et autres
  Publié: (2012)
• A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation.
  par: Stratford, MR, et autres
  Publié: (2012)